ASRS
<ѻý class="page-description">American Society of Retina Specialistsѻý>Case-control study shows reduction in new-onset GA, particularly in nondiabetic patients
Higher rates of progression, interventions, systemic events versus retinopathy without apnea
Significantly lower risk of diabetic macular edema, proliferative diabetic retinopathy
Propensity-matched analysis favored the C3 inhibitor over avacincaptad pegol at 12 and 24 months
Studies show 90% reduction in intravitreal treatment burden, durable effect on vision, anatomy
Positive outcome with UBX-1325 in diabetic macular edema but not wet AMD
AMD treatment burden reduced by 80-90% by implant, intrachoroidal axitinib
Medicare expenditures could jump 15-30%, with similar increases in patients' out-of-pocket costs
Anti-VEGF therapy raises risk of systemic events; retinal effects of diabetes drugs differ
More than a half dozen reports in the last month point to no clear etiology
Also from ASRS: gene therapy for retinitis pigmentosa, anti-VEGF implant matches injection
Longer treatment-free interval with similar vision outcomes versus aflibercept in neovascular AMD
Reoperation rate reduced by three fourths, use expanded to advanced diabetic retinopathy
Subretinal drusenoid deposits found in 85% of patients with AMD and CVD in small study
-
ASRS: American Society of Retina Specialists
July 2024
-
AAO: American Academy of Ophthalmology
November 2023
-
ASCRS: American Society of Cataract & Refractive Surgery
May 2023
-
AAOPT: American Academy of Optometry
October 2017